Adherence to prescribing restrictions for HER2-positive metastatic breast cancer in Australia: A national population-based observational study (2001-2016)
Access status:
Open Access
Type
ArticleAuthor/s
Daniels, BenjaminGirosi, Federico
Tervonen, Hanna
Kiely, Belinda E
Lord, Sally J
Houssami, Nehmat
Pearson, Sallie-Anne
Abstract
Targeted cancer therapy is often complex, involving multiple agents and chemotherapeutic partners. In Australia, prescribing restrictions are put in place to reflect existing evidence of cost-effectiveness of these medicines. As therapeutic options continue to expand, these ...
See moreTargeted cancer therapy is often complex, involving multiple agents and chemotherapeutic partners. In Australia, prescribing restrictions are put in place to reflect existing evidence of cost-effectiveness of these medicines. As therapeutic options continue to expand, these restrictions may not be perceived to align with best practice and it is not known if their use in the real-world clinic adheres to these restrictions. We examined the treatment of women receiving trastuzumab for HER2-positive metastatic breast cancer (HER2+MBC) to determine the extent to which treatment adhered to national prescribing restrictions.
See less
See moreTargeted cancer therapy is often complex, involving multiple agents and chemotherapeutic partners. In Australia, prescribing restrictions are put in place to reflect existing evidence of cost-effectiveness of these medicines. As therapeutic options continue to expand, these restrictions may not be perceived to align with best practice and it is not known if their use in the real-world clinic adheres to these restrictions. We examined the treatment of women receiving trastuzumab for HER2-positive metastatic breast cancer (HER2+MBC) to determine the extent to which treatment adhered to national prescribing restrictions.
See less
Date
2018Source title
PLoS ONEVolume
13Issue
7Publisher
Public Library of ScienceFunding information
NHMRC 1060407
NHMRC 1094325
a Cancer Australia Priority Driven Collaborative Support Scheme (ID: 1050648)
Licence
Creative Commons Attribution 4.0Faculty/School
Faculty of Medicine and Health, Sydney School of Public HealthShare